AZD-5672

Research use only, not for human use.

AZD-5672 is an antagonist of CCR5 with an IC50 of 0.32 nM. AZD-5672 inhibits hERG cardiac ion channel binding and P-gp-mediated digoxin transport with IC50s of 7.3 μM and 32 μM. AZD-5672 can be used in studies about rheumatoid arthritis.

AZD-5672 is an antagonist of CCR5 with an IC50 of 0.32 nM. AZD-5672 inhibits hERG cardiac ion channel binding and P-gp-mediated digoxin transport with IC50s of 7.3 μM and 32 μM. AZD-5672 can be used in studies about rheumatoid arthritis.(In Vitro):In Caco-2 cells, AZD-5672 (0-100 μM) inhibits P-gp-mediated digoxin transport in a concentration-dependent manner.(In Vivo):AZD-5672 (1-2 mg/kg; i.v) shows moderate bioavailability with CI, Vss and t1/2 of 28 mL/min/kg, 5.3 L/kg, and 2.6 h in rats while 18 mL/min/kg, 5.7 L/kg, and 3.9 h in dogs.

AZD-5672 (0, 0.1, 0.3, 1, 3, 10, 30, and 100 μM) inhibits P-gp-mediated digoxin transport in a concentration-dependent manner (mean apparent IC50: 32 μM) in Caco-2 cells.

——

AZD 5672 | AZD5672 | UNII-61XQN688TW

Angiogenesis

HER/HSP

CK2α|serine threonine protein kinase

——

——

780750-65-4

632.78

C32H38F2N2O5S2

>98% (HPLC)

In Vitro:?DMSO : 33.33 mg/mL (52.67 mM)

CCN(C1CCN(CC[C@H](c2ccc(cc2)S(C)(=O)=O)c2cc(F)cc(F)c2)CC1)C(=O)Cc1ccc(cc1)S(C)(=O)=O

——

(-20℃)

With Ice Pack

≥ 2 years